Catherine Penny


  • +44 (0)1483 734275
Catherine Penny

Catherine advises clients on a broad range of commercial disputes including in litigation, international arbitration, adjudication, expert determination and mediation.

Catherine joined Stevens & Bolton in 2013 and became a partner in 2020. She studied law at Cambridge University and the University of Poitiers, France, before qualifying as a solicitor in 2009.

As well as expertise in a variety of contractual disputes, Catherine specialises in life sciences matters and disputes arising out of corporate deals, including earn out disputes. She also has considerable experience of franchising disputes.

Having worked in house for a large corporate client, Catherine understands the pressures faced by in-house teams and offers a solutions-focused approach that clients find invaluable.

Recent highlights include:

  • Advising a global life sciences company on a dispute arising out of the supply of drug products into the Middle East, including allegations of regulatory inadequacies
  • Supporting a UK brand name franchisor on all its franchise dispute matters in the UK across its UK network of 100+ franchisees
  • Advising on a multimillion euro civil fraud claim relating to investments in South America.
  • Acting for the seller of a company when the buyer refused to pay deferred consideration and instead alleged fraudulent misrepresentation

Catherine is a member of the Chartered Institute of Arbitrators and is equally comfortable advising in arbitration as well as court litigation. Catherine is also an active member of the Association Internationale des Jeunes Avocats (AIJA) and she has developed an international reputation for her disputes practice.

Catherine is listed as a “Next Generation Partner” in The Legal 500 for commercial litigation and she is recommended for franchising and commercial litigation.

She has written articles for a number of publications including Global Arbitration Review, The Law Society Gazette, Legal Futures, The Pharma Letter and PharmaTimes.

Search our site